下一代定序市場：市場規模（按細分市場）、份額、監管、報銷、預測（~2033 年）

新一代定序可以透過 DNA 片段化並以自動並行方式對這些片段進行定序來一次對整個基因組進行定序。新一代定序儀可用於全基因組定序、外顯子定序、轉錄組定序（RNA 定序）和多基因組的標靶定序。

測試大量突變以製定個人化治療策略現在已成為常態，並且越來越多地使用下一代定序來評估腫瘤活檢中各種潛在的可靶向突變。

該報告深入探討了全球下一代定序儀市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響以及區域和國家趨勢。

目錄

目前市面上的下一代定序儀及競爭狀況

• 洞察關鍵產業趨勢
• 2015年至2033年按細分市場劃分的下一代定序儀市場總收入及市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域和國家見解

• 下一代定序儀市場的SWOT分析
• 下一代定序市場的競爭動態洞察與趨勢
• 按國家/地區劃分的醫療保健系統概覽
• 各國報銷政策
• 各國醫療技術法規現狀

Abstract

Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Next Generation Sequencers market for the year 2020 and beyond. Next Generation Sequencers allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. Next Generation Sequencers can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

It is now standard to test for a high number of mutations to personalize treatment decisions, use of Next Generation Sequencers that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing.

This model includes High-throughput Next Generation Sequencers, Medium-throughput Next Generation Sequencers, Low-throughput Next Generation Sequencers.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Next Generation Sequencers and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Next Generation Sequencers market revenue by segment and market outlooks from

2015- 2033

• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Next Generation Sequencers market.
• Competitive dynamics insights and trends provided for Next Generation Sequencers market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Illumina Inc, Pacific Biosciences, Thermo Fisher Scientific Inc, Singular Genomics System Inc , and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Next Generation Sequencing (NGS) Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Next Generation Sequencing (NGS) Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable